NRT 16.65 North European Oil Royality Trust $NRT H
Post# of 16
Posted On: 11/13/2014 11:16:20 AM
NRT 16.65 North European Oil Royality Trust $NRT Hit a 52 week low of 16.24 Closing the day 10:45 at 16.65 -0.85 -4.86% With a day low of 16.24 and a total volume of 23,918.
NRT Recent Posts: http://investorshangout.com/North-European-Oi...NRT-52099/
NRT North European Oil Royality Trust Recent Headline News
North European Oil Royalty Trust reports FQ4 results
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 11:55AM CST
NRT: 16.59 (-0.91)
North European Oil Royalty Trust Announces Net Income And Results For The Fourth Quarter Of Fiscal 2014
PR Newswire - Wed Nov 12, 11:29AM CST
North European Oil Royalty Trust (NYSE: NRT) reported the net income and results for the fourth quarter of fiscal 2014 which appear below compared with the fourth quarter of fiscal 2013.
NRT: 16.59 (-0.91)
24.3% Return Seen to Date on SmarTrend North European Oil Royalty Trust Call (NRT)
Comtex SmarTrend(R) - Wed Nov 12, 11:04AM CST
SmarTrend identified a Downtrend for North European Oil Royalty Trust (NYSE:NRT) on May 20th, 2014 at $22.94. In approximately 6 months, North European Oil Royalty Trust has returned 24.32% as of today's recent price of $17.36.
NRT: 16.59 (-0.91)
North European Oil Royalty Trust Has Returned 20.1% Since SmarTrend Recommendation (NRT)
Comtex SmarTrend(R) - Wed Nov 05, 9:39AM CST
SmarTrend identified a Downtrend for North European Oil Royalty Trust (NYSE:NRT) on May 20th, 2014 at $22.94. In approximately 6 months, North European Oil Royalty Trust has returned 20.05% as of today's recent price of $18.34.
NRT: 16.59 (-0.91)
North European Oil Royalty Trust declares $0.39 distribution
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 11:26AM CDT
NRT: 16.59 (-0.91)
North European Oil Royalty Trust Announces The Distribution For The Fourth Quarter Of Fiscal 2014
PR Newswire - Thu Oct 30, 11:11AM CDT
The Trustees of North European Oil Royalty Trust (NYSE: NRT) today announced a quarterly distribution of $0.39 per unit for the fourth quarter of fiscal 2014, payable on November 26, 2014 to holders of record on November 14, 2014. Natural gas sold during the third calendar quarter of 2014 is the primary source of royalty income on which the November distribution is based.
NRT: 16.59 (-0.91)
North European Oil Royalty Trust Shares Down 18.2% Since SmarTrend's Sell Call (NRT)
Comtex SmarTrend(R) - Wed Oct 29, 9:14AM CDT
SmarTrend identified a Downtrend for North European Oil Royalty Trust (NYSE:NRT) on May 20th, 2014 at $22.94. In approximately 5 months, North European Oil Royalty Trust has returned 18.22% as of today's recent price of $18.76.
NRT: 16.59 (-0.91)
Shares of NRT Down 14.8% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Oct 21, 4:48PM CDT
SmarTrend identified a Downtrend for North European Oil Royalty Trust (NYSE:NRT) on May 20th, 2014 at $22.94. In approximately 5 months, North European Oil Royalty Trust has returned 14.81% as of today's recent price of $19.54.
NRT: 16.59 (-0.91)
Downtrend Call Working As North European Oil Royalty Trust Stock Falls 12.8% (NRT)
Comtex SmarTrend(R) - Tue Oct 07, 9:55AM CDT
SmarTrend identified a Downtrend for North European Oil Royalty Trust (NYSE:NRT) on May 20th, 2014 at $22.94. In approximately 5 months, North European Oil Royalty Trust has returned 12.82% as of today's recent price of $20.00.
NRT: 16.59 (-0.91)
North European Oil Royalty Trust Has Returned 9.8% Since SmarTrend Recommendation (NRT)
Comtex SmarTrend(R) - Mon Sep 29, 5:23PM CDT
SmarTrend identified a Downtrend for North European Oil Royalty Trust (NYSE:NRT) on May 20th, 2014 at $22.94. In approximately 4 months, North European Oil Royalty Trust has returned 9.78% as of today's recent price of $20.70.
NRT: 16.59 (-0.91)
North European Oil Royalty Trust Announces Net Income And Results For The Third Quarter Of Fiscal 2014
PR Newswire - Wed Aug 13, 1:02PM CDT
North European Oil Royalty Trust (NYSE: NRT) reported the net income and results for the third quarter of fiscal 2014 which appear below compared with the third quarter of fiscal 2013.
NRT: 16.59 (-0.91)
Novogen awarded funding in support of Muscular Dystrophy research studies using super-benzopyran compounds
M2 - Wed Aug 13, 5:18AM CDT
Biotechnology company Novogen (ASX:NRT)(NASDAQ:NVGN) said on Tuesday that it has received funding from the FSHD Global Research Foundation to find effective treatments for a range of musculo-degenerative diseases, including facioscapulohumeral dystrophy (FSHD), a form of muscular dystrophy and genetic skeletal muscle hereditary disease.
NVGN: 2.63 (-0.10), NRT: 16.59 (-0.91)
North European Oil Royalty Trust Announces The Distribution For The Third Quarter Of Fiscal 2014
PR Newswire - Thu Jul 31, 8:33AM CDT
The Trustees of North European Oil Royalty Trust (NYSE: NRT) announced today a quarterly distribution of $0.46 per unit for the third quarter of fiscal 2014, payable on August 27, 2014 to holders of record on August 15, 2014. Natural gas sold during the second calendar quarter of 2014 is the primary source of royalty income on which the August 2014 distribution is based.
NRT: 16.59 (-0.91)
3 Hold-Rated Dividend Stocks: MCC, TCRD, NRT
at The Street - Mon Jul 28, 10:30AM CDT
These 3 dividend stocks are rated a Hold by TheStreet
TCRD: 13.17 (+0.06), MCC: 11.77 (+0.07), NRT: 16.59 (-0.91)
3 Hold-Rated Dividend Stocks: RNO, GAIN, NRT
at The Street - Mon Jul 07, 10:30AM CDT
These 3 dividend stocks are rated a Hold by TheStreet
RNO: 3.08 (-0.01), NRT: 16.59 (-0.91), GAIN: 7.32 (-0.04)
3 Hold-Rated Dividend Stocks: SFL, NRP, NRT
at The Street - Thu Jun 26, 10:30AM CDT
These 3 dividend stocks are rated a Hold by TheStreet
NRP: 12.81 (-0.02), SFL: 17.23 (-0.07), NRT: 16.59 (-0.91)
NYSE stocks posting largest volume decreases
AP - Fri Mar 21, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest volume decliners on New York Stock Exchange at the close of trading:
NRT: 16.59 (-0.91), DKL: 40.16 (-0.23)
Novogen and CanTx's experimental drug Trx-1 passes important test to fight abdominal cancers
M2 - Wed Mar 19, 7:56AM CDT
Australian biotechnology company Novogen (ASX:NRT)(NASDAQ:NVGN) revealed on Tuesday that its lead candidate drug, Trx-1, has demonstrated a potent anti-cancer effect in mice xenografted with human ovarian cancer stem cells in partnership with CanTx.
NVGN: 2.63 (-0.10), NRT: 16.59 (-0.91)
NRT Recent Posts: http://investorshangout.com/North-European-Oi...NRT-52099/
NRT North European Oil Royality Trust Recent Headline News
North European Oil Royalty Trust reports FQ4 results
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 11:55AM CST
NRT: 16.59 (-0.91)
North European Oil Royalty Trust Announces Net Income And Results For The Fourth Quarter Of Fiscal 2014
PR Newswire - Wed Nov 12, 11:29AM CST
North European Oil Royalty Trust (NYSE: NRT) reported the net income and results for the fourth quarter of fiscal 2014 which appear below compared with the fourth quarter of fiscal 2013.
NRT: 16.59 (-0.91)
24.3% Return Seen to Date on SmarTrend North European Oil Royalty Trust Call (NRT)
Comtex SmarTrend(R) - Wed Nov 12, 11:04AM CST
SmarTrend identified a Downtrend for North European Oil Royalty Trust (NYSE:NRT) on May 20th, 2014 at $22.94. In approximately 6 months, North European Oil Royalty Trust has returned 24.32% as of today's recent price of $17.36.
NRT: 16.59 (-0.91)
North European Oil Royalty Trust Has Returned 20.1% Since SmarTrend Recommendation (NRT)
Comtex SmarTrend(R) - Wed Nov 05, 9:39AM CST
SmarTrend identified a Downtrend for North European Oil Royalty Trust (NYSE:NRT) on May 20th, 2014 at $22.94. In approximately 6 months, North European Oil Royalty Trust has returned 20.05% as of today's recent price of $18.34.
NRT: 16.59 (-0.91)
North European Oil Royalty Trust declares $0.39 distribution
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 11:26AM CDT
NRT: 16.59 (-0.91)
North European Oil Royalty Trust Announces The Distribution For The Fourth Quarter Of Fiscal 2014
PR Newswire - Thu Oct 30, 11:11AM CDT
The Trustees of North European Oil Royalty Trust (NYSE: NRT) today announced a quarterly distribution of $0.39 per unit for the fourth quarter of fiscal 2014, payable on November 26, 2014 to holders of record on November 14, 2014. Natural gas sold during the third calendar quarter of 2014 is the primary source of royalty income on which the November distribution is based.
NRT: 16.59 (-0.91)
North European Oil Royalty Trust Shares Down 18.2% Since SmarTrend's Sell Call (NRT)
Comtex SmarTrend(R) - Wed Oct 29, 9:14AM CDT
SmarTrend identified a Downtrend for North European Oil Royalty Trust (NYSE:NRT) on May 20th, 2014 at $22.94. In approximately 5 months, North European Oil Royalty Trust has returned 18.22% as of today's recent price of $18.76.
NRT: 16.59 (-0.91)
Shares of NRT Down 14.8% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Oct 21, 4:48PM CDT
SmarTrend identified a Downtrend for North European Oil Royalty Trust (NYSE:NRT) on May 20th, 2014 at $22.94. In approximately 5 months, North European Oil Royalty Trust has returned 14.81% as of today's recent price of $19.54.
NRT: 16.59 (-0.91)
Downtrend Call Working As North European Oil Royalty Trust Stock Falls 12.8% (NRT)
Comtex SmarTrend(R) - Tue Oct 07, 9:55AM CDT
SmarTrend identified a Downtrend for North European Oil Royalty Trust (NYSE:NRT) on May 20th, 2014 at $22.94. In approximately 5 months, North European Oil Royalty Trust has returned 12.82% as of today's recent price of $20.00.
NRT: 16.59 (-0.91)
North European Oil Royalty Trust Has Returned 9.8% Since SmarTrend Recommendation (NRT)
Comtex SmarTrend(R) - Mon Sep 29, 5:23PM CDT
SmarTrend identified a Downtrend for North European Oil Royalty Trust (NYSE:NRT) on May 20th, 2014 at $22.94. In approximately 4 months, North European Oil Royalty Trust has returned 9.78% as of today's recent price of $20.70.
NRT: 16.59 (-0.91)
North European Oil Royalty Trust Announces Net Income And Results For The Third Quarter Of Fiscal 2014
PR Newswire - Wed Aug 13, 1:02PM CDT
North European Oil Royalty Trust (NYSE: NRT) reported the net income and results for the third quarter of fiscal 2014 which appear below compared with the third quarter of fiscal 2013.
NRT: 16.59 (-0.91)
Novogen awarded funding in support of Muscular Dystrophy research studies using super-benzopyran compounds
M2 - Wed Aug 13, 5:18AM CDT
Biotechnology company Novogen (ASX:NRT)(NASDAQ:NVGN) said on Tuesday that it has received funding from the FSHD Global Research Foundation to find effective treatments for a range of musculo-degenerative diseases, including facioscapulohumeral dystrophy (FSHD), a form of muscular dystrophy and genetic skeletal muscle hereditary disease.
NVGN: 2.63 (-0.10), NRT: 16.59 (-0.91)
North European Oil Royalty Trust Announces The Distribution For The Third Quarter Of Fiscal 2014
PR Newswire - Thu Jul 31, 8:33AM CDT
The Trustees of North European Oil Royalty Trust (NYSE: NRT) announced today a quarterly distribution of $0.46 per unit for the third quarter of fiscal 2014, payable on August 27, 2014 to holders of record on August 15, 2014. Natural gas sold during the second calendar quarter of 2014 is the primary source of royalty income on which the August 2014 distribution is based.
NRT: 16.59 (-0.91)
3 Hold-Rated Dividend Stocks: MCC, TCRD, NRT
at The Street - Mon Jul 28, 10:30AM CDT
These 3 dividend stocks are rated a Hold by TheStreet
TCRD: 13.17 (+0.06), MCC: 11.77 (+0.07), NRT: 16.59 (-0.91)
3 Hold-Rated Dividend Stocks: RNO, GAIN, NRT
at The Street - Mon Jul 07, 10:30AM CDT
These 3 dividend stocks are rated a Hold by TheStreet
RNO: 3.08 (-0.01), NRT: 16.59 (-0.91), GAIN: 7.32 (-0.04)
3 Hold-Rated Dividend Stocks: SFL, NRP, NRT
at The Street - Thu Jun 26, 10:30AM CDT
These 3 dividend stocks are rated a Hold by TheStreet
NRP: 12.81 (-0.02), SFL: 17.23 (-0.07), NRT: 16.59 (-0.91)
NYSE stocks posting largest volume decreases
AP - Fri Mar 21, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest volume decliners on New York Stock Exchange at the close of trading:
NRT: 16.59 (-0.91), DKL: 40.16 (-0.23)
Novogen and CanTx's experimental drug Trx-1 passes important test to fight abdominal cancers
M2 - Wed Mar 19, 7:56AM CDT
Australian biotechnology company Novogen (ASX:NRT)(NASDAQ:NVGN) revealed on Tuesday that its lead candidate drug, Trx-1, has demonstrated a potent anti-cancer effect in mice xenografted with human ovarian cancer stem cells in partnership with CanTx.
NVGN: 2.63 (-0.10), NRT: 16.59 (-0.91)
(0)
(0)